MedTrace Logo

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 190

Last updated 2021-02-18

Study results available
· View outcomes & findings →

Summary

The main objective of this study is to evaluate the efficacy of Ivermectin 1% cream (IVM) associated with Brimonidine 0.33% gel (Br) compared with the association of their respective vehicles in the treatment of moderate to severe rosacea.

Conditions

  • Rosacea

Interventions

DRUG

Brimonidine 0.33% gel (Br)

OTHER

CD07805/47 (Br) placebo gel

DRUG

Ivermectin 1% cream (IVM)

OTHER

CD5024 (IVM) placebo cream

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-31
Primary Completion
2016-09-30
Completion
2016-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02616250 on ClinicalTrials.gov